Neil Gibson
Directeur/Membre du Conseil chez INSTIL BIO, INC.
Fortune : 515 846 $ au 30/04/2024
Profil
Neil W.
Gibson is currently an Independent Director at Shattuck Labs, Inc., a Lead Independent Director at Instil Bio, Inc., a Director at Cullinan MICA, Inc., a Director at Causeway Therapeutics Ltd., a Director at Cullinan Mica Corp.
(Massachusetts), and the Chief Scientific Officer at Silarus Therapeutics, Inc. Previously, Dr. Gibson served as the President & Chief Executive Officer of Cullinan Mica Corp., the President & Co-Chief Executive Officer of Adanate, Inc., the Director of Cancer Research at Bayer AG, an Independent Director at TCR2 Therapeutics, Inc., a Director at CytoSen Therapeutics, Inc., the Chief Scientific Officer & Vice President at OSI Pharmaceuticals, Inc., the Chief Scientific Officer-Oncology Research Unit at Pfizer Inc., an Associate Professor at the University of Southern California, the Chief Scientific Officer of Regulus Therapeutics, Inc., the Chief Development Officer & Senior Vice President of BioAtla, Inc., and the Chief Scientific Officer & Senior Vice President of COI Pharmaceuticals, Inc. Dr. Gibson obtained an undergraduate degree from the University of Strathclyde and a doctorate degree from the University of Aston.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SHATTUCK LABS, INC.
0,11% | 01/04/2024 | 52 745 ( 0,11% ) | 515 846 $ | 30/04/2024 |
INSTIL BIO, INC.
-.--% | 16/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Neil Gibson
| Sociétés | Poste | Début |
|---|---|---|
| SHATTUCK LABS, INC. | Directeur/Membre du Conseil | 01/11/2016 |
| INSTIL BIO, INC. | Directeur/Membre du Conseil | 01/06/2020 |
Cullinan MICA, Inc.
 Cullinan MICA, Inc. Investment ManagersFinance Cullinan MICA, Inc. develops immune-oncology antibody. The company is headquartered in the United States. | Directeur/Membre du Conseil | 01/01/2020 |
Causeway Therapeutics Ltd.
 Causeway Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Causeway Therapeutics Ltd. operates as a biotechnology company. It develops drugs for the treatment for patients. The company was founded by Derek S. Gilchrist and Neal L. Millar and is headquartered in Glasgow, the United States. | Directeur/Membre du Conseil | - |
Silarus Therapeutics, Inc.
 Silarus Therapeutics, Inc. BiotechnologyHealth Technology Silarus Therapeutics, Inc. develops therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. The company was founded by Tomas Ganz, Sanford J. Madigan, and Elizabeta Nemeth in May 19, 2014 and is headquartered in La Jolla, CA. | Directeur Technique/Scientifique/R&D | - |
Cullinan Mica Corp.
 Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Part of Cullinan Therapeutics, Inc., Cullinan Mica Corp. is a company that provides worldwide rights to CLN-619. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. | Directeur/Membre du Conseil | - |
Anciens postes connus de Neil Gibson
| Sociétés | Poste | Fin |
|---|---|---|
| TCR2 THERAPEUTICS INC. | Directeur/Membre du Conseil | 01/06/2023 |
COI Pharmaceuticals, Inc.
 COI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology COI Pharmaceuticals, Inc. provides life science investors. It offers research and development infrastructure and industry mentors to the portfolio companies of Avalon Ventures. The company was founded in 2013 and is headquartered in La Jolla, CA. | Directeur Technique/Scientifique/R&D | 01/12/2021 |
Adanate, Inc.
 Adanate, Inc. BiotechnologyHealth Technology Adanate, Inc. develops antibody therapeutics. The CEO of the American company is Chris Griffith. | Directeur Général | - |
| ░░░░░░░░ ░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Neil Gibson
| University of Aston | Doctorate Degree |
| University of Strathclyde | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| REGULUS THERAPEUTICS INC. | Health Technology |
| BAYER AG | Health Technology |
| BIOATLA, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| SHATTUCK LABS, INC. | Health Technology |
| INSTIL BIO, INC. | Health Technology |
| Entreprise privées | 11 |
|---|---|
OSI Pharmaceuticals, Inc.
 OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
COI Pharmaceuticals, Inc.
COI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology COI Pharmaceuticals, Inc. provides life science investors. It offers research and development infrastructure and industry mentors to the portfolio companies of Avalon Ventures. The company was founded in 2013 and is headquartered in La Jolla, CA. | Health Technology |
TCR2 Therapeutics, Inc.
 TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. | Health Technology |
CytoSen Therapeutics, Inc.
 CytoSen Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services CytoSen Therapeutics, Inc. develops natural killer (NK) cell therapeutics for cancer. It offers nanoparticle processing technology which enables improved ex vivo expansion and activation of NK-cells supporting multiple high dose infusions with anti-cancer cytotoxicity. The company was founded by Stefan O. Ciurea, Dean Lee and Robert Igarashi and is headquartered in Orlando, FL. | Commercial Services |
Cullinan Mica Corp.
 Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology PDI Therapeutics, Inc. develops therapeutics that enhances the body’s ability to recognize and destroy tumor cells. The company is headquartered in La Jolla, CA. | Health Technology |
Adanate, Inc.
Adanate, Inc. BiotechnologyHealth Technology Adanate, Inc. develops antibody therapeutics. The CEO of the American company is Chris Griffith. | Health Technology |
Silarus Therapeutics, Inc.
Silarus Therapeutics, Inc. BiotechnologyHealth Technology Silarus Therapeutics, Inc. develops therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. The company was founded by Tomas Ganz, Sanford J. Madigan, and Elizabeta Nemeth in May 19, 2014 and is headquartered in La Jolla, CA. | Health Technology |
| British Pharmaceutical Students Association | |
Causeway Therapeutics Ltd.
Causeway Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Causeway Therapeutics Ltd. operates as a biotechnology company. It develops drugs for the treatment for patients. The company was founded by Derek S. Gilchrist and Neal L. Millar and is headquartered in Glasgow, the United States. | Health Technology |
Cullinan MICA, Inc.
Cullinan MICA, Inc. Investment ManagersFinance Cullinan MICA, Inc. develops immune-oncology antibody. The company is headquartered in the United States. | Finance |
Cullinan Mica Corp.
Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Part of Cullinan Therapeutics, Inc., Cullinan Mica Corp. is a company that provides worldwide rights to CLN-619. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. | Health Technology |